Indeed, it has been shown that PI3K inhibitors and CHK1 inhibitors combination treatments exhibit remarkably higher cytotoxicity in high-grade serous ovarian carcinoma cells compared with each individual drug alone, with evidence of increased DNA damage, chromosomal breaks, and mitotic catastrophe (135). The gene discussed is PIK3CA; the disease is ovarian serous carcinoma.